CMPD is a micro-cap health care technology company trading on the OTC Pink market. This week the stock closed at $6.22, down about 5% on the week despite a 6.3% bounce on Wednesday alone. With a market cap of roughly $7.8 million, thin liquidity defines nearly every aspect of this name's trading profile.
The most notable development this week is the cost to borrow. After sliding sharply from above 5% in mid-March to just 1.4% by April 1, borrowing costs have more than tripled over the past month, climbing back to 4.3% as of April 28. That rebound — up about 1.5% on the week — suggests renewed demand for borrows despite the stock's recent price weakness. Availability, however, tells a very different story: at 9,999% of short interest, the lending pool is effectively unrestricted. There are vastly more shares available to borrow than are currently shorted, so the borrow-cost move is not being driven by a shortage of supply.
Short positioning is modest and not a primary driver. Short interest amounts to just 0.41% of the free float — roughly 5,475 shares in absolute terms — and has edged up 6% over the past week after falling 17% over the prior month. The mid-March short interest peak, when shares short ran near 6,600, has been unwound. What remains is a residual, low-conviction position. The ORTEX short score of 31.7 out of 100 is consistent with that picture: no meaningful short-side pressure.
With no analyst coverage, no upcoming earnings on the calendar, and insider data last recorded in 2007, the story on CMPD this week is largely one of thin-market mechanics. The stock's one-month decline of 7% has come without any obvious catalyst in the news flow, and the only recent headline tagged to the company was a general hospital-care licensing industry roundup from late April. Factor scores and valuation multiples flagged in the data are too stale to be meaningful — the most recent valuation data dates to 2012.
The price action itself is the main thing to watch. The intraday swings — a 6% single-day move in either direction is not unusual for a name this size — can be driven by very small order flow. The borrow-cost trajectory, and whether it continues to climb back toward the February highs above 5%, is the one data point worth monitoring for any sign that positioning is changing.
See the live data behind this article on ORTEX.
Open CMPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
